These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 26547456)
1. Predicting the Overuse of PCSK-9 Inhibitors. Rodriguez-Gutierrez R; Shah ND; Montori VM JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456 [No Abstract] [Full Text] [Related]
2. Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease. Paraskevas KI; Mukherjee D; Papas TT Curr Vasc Pharmacol; 2024; 22(1):8-10. PubMed ID: 38037835 [No Abstract] [Full Text] [Related]
3. PCSK9 Pleiotropism: In the Same Vein as Statins. Park AC; Zhang X; Yeh YS; Razani B Circ Res; 2022 Nov; 131(11):890-892. PubMed ID: 36356112 [No Abstract] [Full Text] [Related]
5. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Blom D; Seidah NG; Honarpour N; Lira A; Xue A; Chiruvolu P; Jackson S; Di M; Peach M; Somaratne R; Wasserman SM; Scott R; Stein EA J Lipid Res; 2016 Jun; 57(6):1086-96. PubMed ID: 27102113 [TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibitors in the prevention of cardiovascular disease. Latimer J; Batty JA; Neely RD; Kunadian V J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708 [TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. McDonagh M; Peterson K; Holzhammer B; Fazio S J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792 [TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874 [TBL] [Abstract][Full Text] [Related]
9. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873 [TBL] [Abstract][Full Text] [Related]